Nish Parekh and Michael Garel give Highway to Health a tour of Omnicell’s Innovation Lab to show how healthcare automation ...

OMCL stays on investors' radar due to its strong 2025 growth targets with automation and tech services, but faces margin risks from macro and competitive headwinds.

In the preceding three months, 7 analysts have released ratings for Omnicell OMCL, presenting a wide array of perspectives from bullish to bearish. The table below offers a condensed view of their ...

Omnicell’s prior full-year 2025 guidance had accounted for a significant impact from tariffs on Chinese imports, which play a role in the manufacturing process for its products. The company imports ...

Omnicell has also launched a $75 million share repurchase program. Specifically, the company has updated its full-year 2025 adjusted EBITDA guidance from the range of $100-$145 million to $120 ...

Shares of healthcare tech company Omnicell (NASDAQ:OMCL) jumped 5.9% in the afternoon session after the company reported impressive preliminary second quarter 2025 and full-year profit guidance ...

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in ...

Wells Fargo upgraded Omnicell (NASDAQ:OMCL) to Overweight from Equal Weight on Wednesday, citing a compelling risk-reward setup in the shares of the Fort Worth, Texas-based vendor of pharmacy ...

These products, which leverage RFID tracking and intelligent software workflows, expand Omnicell’s connected platform that is intended to automate medication management processes and deliver ...

Company Establishes New Hub Dedicated to Addressing Challenges Across the Medication Journey Omnicell, Inc. (Nasdaq:OMCL), (“Omnicell” or the “Company”), a leader in transforming the ...